Please provide your email address to receive an email when new articles are posted on . TrenibotulinumtoxinE is a fast-acting, short-term neurotoxin for treatment of glabellar lines. The FDA’s ...
The U.S. Food and Drug Administration has published more than 200 complete response letters, or decision letters, sent as replies to drug and biological product applications submitted to the agency ...
Ultragenyx received a Complete Response Letter from the FDA regarding its UX111 therapy for Sanfilippo syndrome type A, citing manufacturing observations. Ultragenyx Pharmaceutical Inc. announced that ...
Good day, and thank you for standing by. Welcome to the Disc Medicine Corporate Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the ...
Employers may dread a knock on the door from an Occupational Safety and Health investigator, but in many circumstances, the first contact with OSHA is through a letter rather than an in-person ...
On November 2, 2025, the FDA issued a complete response letter (CRL) for Alvotech’s abbreviated Biologics License Application (aBLA) for its proposed Simponi ® (golimumab) biosimilar AVT05. The CRL ...
Lexicon Pharmaceuticals announced that it received a complete response letter (CRL) from the FDA regarding its New Drug Application for Zynquista™ (sotagliflozin), which was proposed as an adjunct to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results